Short-Term Azithromycin Treatment Promotes Cornea Allograft Survival in the Rat
Figure 1
(A) Clear graft survival following keratoplasty is shown by Kaplan-Meier estimator. Treatment with miglyol (group 4) led to rejection at day 13 [12.5–13.5], whereas with AZM (group 3), no rejection was detected. When treating the allogeneic transplanted animals with AZM (group 2), rejection occurred at day 28.5 [20.3–36.6] postoperatively. AZM allogeneic compared with the control with miglyol did promote graft survival (p < 0.004).
(B) Treatment with ofloxacin (group 5) led to rejection at day 13, similar to miglyol, while AZM improved graft survival significantly.